{"id":"NCT02562066","sponsor":"Catalyst Pharmaceuticals, Inc.","briefTitle":"Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes","officialTitle":"A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01","primaryCompletion":"2019-08","completion":"2019-10","firstPosted":"2015-09-29","resultsPosted":"2021-04-02","lastUpdate":"2021-04-02"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Myasthenic Syndromes, Congenital"],"interventions":[{"type":"DRUG","name":"amifampridine phosphate","otherNames":["3,4 diaminopyridine phosphate, Firdapseâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"amifampridine phosphate -placebo","type":"EXPERIMENTAL"},{"label":"placebo - amifampridine phosphate","type":"EXPERIMENTAL"}],"summary":"This randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 and above) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment.","primaryOutcome":{"measure":"Subject Global Impression (SGI) Score Summary: Mann-Whitney Main Effects Test Results; SGI Score Mixed Model Analysis","timeFrame":"Study Period 1: Baseline (Day 0), Day 8; Study Period 2: Baseline (Day 21), Day 29","effectByArm":[{"arm":"Amifampridine Phosphate - Placebo","deltaMin":-0.13,"sd":1.81},{"arm":"Placebo - Amifampridine Phosphate","deltaMin":-1.75,"sd":2.12}],"pValues":[{"comp":"OG000 vs OG001","p":"0.085"},{"comp":"OG000","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":20},"commonTop":["Vomiting","Nasopharyngitis","Headache","Nausea","Upper respiratory tract infection"]}}